 |
Products |  |
Diseases | | Products |
|
Trials |  |
News |  |
- | ABP-100 / Abpro Bio
Journal: VA-ECMO With IABP is Associated With Better Outcome Than VA-ECMO Alone in the Treatment of Cardiogenic Shock in ST-Elevation Myocardial Infarction. (Pubmed Central) - Sep 19, 2021
In STEMI complicated by CS, VA-ECMO + IABP leads to a lower observed mortality and higher observed good neurological outcome.
- Eylea (aflibercept intravitreal) / Bayer, Regeneron
[VIRTUAL] A tetravalent bispecific anti-angiopoietin-2/anti-VEGF antibody suppresses neovascular lesion and leakage in a laser-induced rat choroidal neovascularization model () - May 13, 2021 - Abstract #ARVO2021ARVO_1112;
Our study demonstrated that ABP-201 was beneficial for reducing neovascular lesion formation and vascular leakage in rat model of laser-induced CNV. These results pave the way to begin to utilize this bispecific antibody, engineered to improve both efficacy and durability compared to current VEGF therapies, for the treatment of wet-AMD and DME, as well as other angiogenic eye diseases.
- | Abraxane (albumin-bound paclitaxel) / BMS, Otsuka, gemcitabine / Generic mfg.
Journal: Dose-modified gemcitabine plus nab-paclitaxel front-line in advanced pancreatic ductal adenocarcinoma with baseline hyperbilirubinemia. (Pubmed Central) - Mar 17, 2020
No admissions related to toxicity were found. Our analysis revealed safety with NabP (median dose =100 mg/m) + GEM (median dose =600 mg/m at fixed-dose rate) given predominately biweekly in patients with a baseline elevated total bilirubin (≥2 mg/dL).
- ABP-100 - Abpro Therap, Memorial Sloan / Kettering Cancer Center
Claudin18.2 bispecific T-cell engager for gastric cancer immunotherapy (Prince George's Exhibition Halls AB) - Oct 2, 2019 - Abstract #SITC2019SITC_969;
Lead CLDN18.2 clones, ABP150-1 and ABP150-2 as T-cell engagers showed CLDN18.2 specific binding and functionally weak CD3 binding (in the absence of target ) resulting in strong TDCC response only in the presence of CLDN18.2 tumors. Taken together, we conclude that these two clones are expected to efficiently clear CLDN18.2 tumors without cytokine release syndrome.